NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









KAHR Medical

KAHR Medical

Private
IsraelHealthcare & Life Scienceshttps://kahrbio.base44.app/

Last Round

VC Round

Jan 8, 2026

Est. Valuation

$16M

Total Funding Raised

$47M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

KAHR Medical is a biotechnology company that develops dual-targeting fusion protein therapeutics designed to activate both the innate and adaptive immune systems to treat cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologyfusion proteinbiotechcancer drugclinical trialscheckpoint inhibitionsolid tumorsdrug developmentDSP107biopharmacolorectal cancerimmune activationtherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KAHR Medical Comps

Public and private peers based on sector, stage, and business model.

KAHR Medical comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

KAHR Medical Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 8, 2026
Series BOct 14, 2025
Series D ExtensionNov 17, 2022
VC RoundJun 16, 2021
VC RoundFeb 25, 2020
Series B
Dec 15, 2015

KAHR Medical Investors

Notable investors and investment history

KAHR Medical investors
InvestorRounds
DSC InvestmentSeries B
Korea Investment PartnersSeries B
Mirae AssetVC Round, Series D Extension
Israel Innovation AuthoritySeed
Flerie InvestVC Round
The University of Texas MD Anderson Cancer CenterVC Round
Consensus Business GroupSeries D Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 14, 2025

    $22M round completed.

  • Sep 11, 2024

    Grew 57% QoQ, from 21 to 33 employees.

KAHR Medical Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

KAHR Medical Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about KAHR Medical's valuation, stock price, and market status.

Firmographic Details

HeadquartersIsrael
Employee Range49
Year Founded2005
Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.